Physician profile
Brian Uzomba
NPI 1972232759
$296.23
in general payments reported to CMS, 2019-2025
12 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $50.43 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47.90 | 2025 | |
| Lilly USA, LLC | $36.81 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $36.34 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $27.81 | 2025 | |
| Exact Sciences Corporation | $27.73 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $23.87 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2025 | |
| Lundbeck LLC | $17.11 | 2025 | Rexulti |
| Novo Nordisk INC | $16.24 | 2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $14.92 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $12.95 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Uzomba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.